首次使用芬戈莫德治疗多发性硬化症时心血管并发症的实际经验。
The real-life experience with cardiovascular complications in the first dose of fingolimod for multiple sclerosis.
作者信息
Fragoso Yara Dadalti, Arruda Christian Cardoso, Arruda Walter Oleschko, Brooks Joseph Bruno Bidin, Damasceno Alfredo, Damasceno Carlos Augusto de Albuquerque, Finkelsztejn Alessandro, Finkelsztejn Juliana, Gama Paulo Diniz da, Giacomo Maria Cristina Brandão, Gomes Sidney, Goncalves Marcus Vinicius Magno, Matta Andre Palma da Cunha, de Morais Marilia Manprim, Oliveira Enedina Maria Lobato de, Ribeiro Yuna, Sato Henry Koiti, Tauil Carlos Bernardo
机构信息
Departamento de Neurologia, Universidade Metropolitana de Santos, Santos, SP, Brazil.
Departamento de Neurologia, Universidade Positivo, Curitiba, PR, Brazil.
出版信息
Arq Neuropsiquiatr. 2014 Sep;72(9):712-4. doi: 10.1590/0004-282x20140102.
Fingolimod is a new and efficient treatment for multiple sclerosis (MS). The drug administration requires special attention to the first dose, since cardiovascular adverse events can be observed during the initial six hours of fingolimod ingestion. The present study consisted of a review of cardiovascular data on 180 patients with MS receiving the first dose of fingolimod. The rate of bradycardia in these patients was higher than that observed in clinical trials with very strict inclusion criteria for patients. There were less than 10% of cases requiring special attention, but no fatal cases. All but one patient continued the treatment after this initial dose. This is the first report on real-life administration of fingolimod to Brazilian patients with MS, and one of the few studies with these characteristics in the world.
芬戈莫德是一种治疗多发性硬化症（MS）的新型高效药物。给药时需特别关注首剂，因为在摄入芬戈莫德后的最初6小时内可观察到心血管不良事件。本研究对180例接受首剂芬戈莫德治疗的MS患者的心血管数据进行了回顾。这些患者的心动过缓发生率高于纳入标准非常严格的临床试验中观察到的发生率。需要特别关注的病例不到10%，但无死亡病例。除1例患者外，所有患者在首剂给药后继续接受治疗。这是关于巴西MS患者实际使用芬戈莫德的首份报告，也是世界上为数不多的具有这些特征的研究之一。
Zotero 插件